Top Banner
125:583 Biointerfacial Characterization of Nanoparticles and Nanoscale Biointerfaces II P. Moghe
26

125:583 Biointerfacial Characterization of Nanoparticles and Nanoscale Biointerfaces II P. Moghe.

Dec 21, 2015

Download

Documents

Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: 125:583 Biointerfacial Characterization of Nanoparticles and Nanoscale Biointerfaces II P. Moghe.

125:583

Biointerfacial Characterization of Nanoparticles and

Nanoscale Biointerfaces II

P. Moghe

Page 2: 125:583 Biointerfacial Characterization of Nanoparticles and Nanoscale Biointerfaces II P. Moghe.

Outline

• Measuring surface charge/zeta potentials on nanoparticles (Anthony)

• Characterization of biofunctionalization of nanoparticles (Moghe)

• Characterization of cell adhesive responses to biofunctional nanoscale interfaces (Moghe)

Page 3: 125:583 Biointerfacial Characterization of Nanoparticles and Nanoscale Biointerfaces II P. Moghe.

How to characterize biofunctionalization of

nanoparticles?

• Use of fluorometry• Use ELISA for biospecific signal

• Use DLS if the biocomplexation leads to change in size.

• Electron Microscopy; AFM for morphological changes

• Modeling

Page 4: 125:583 Biointerfacial Characterization of Nanoparticles and Nanoscale Biointerfaces II P. Moghe.

Example: Characterization of Biofunctionalization

• Example from Sharma et al., In Review, Biomaterials (2005).

• Albumin nanoparticles (ANP) were derivatized with fibronectin fragments and then adsorbed on TCPS.

• Albumin-specific ELISA was used to quantify the amount of backbone NPs, while FNf-specific ELISA was used to quantify the biofunctionalization.

Page 5: 125:583 Biointerfacial Characterization of Nanoparticles and Nanoscale Biointerfaces II P. Moghe.

Ligand Loading on Nanoparticles

Example: Fibronectin fragment derivatized to albumin

nanocarriers (ANC)

Page 6: 125:583 Biointerfacial Characterization of Nanoparticles and Nanoscale Biointerfaces II P. Moghe.

Exposure of bioactive sites on nanoparticle-derivatized ligands

Page 7: 125:583 Biointerfacial Characterization of Nanoparticles and Nanoscale Biointerfaces II P. Moghe.
Page 8: 125:583 Biointerfacial Characterization of Nanoparticles and Nanoscale Biointerfaces II P. Moghe.

Particle Sizing Following PEGylation

Page 9: 125:583 Biointerfacial Characterization of Nanoparticles and Nanoscale Biointerfaces II P. Moghe.

Morphology of biofunctionalized

nanoparticles

Page 10: 125:583 Biointerfacial Characterization of Nanoparticles and Nanoscale Biointerfaces II P. Moghe.

Ligand Concentration

Page 11: 125:583 Biointerfacial Characterization of Nanoparticles and Nanoscale Biointerfaces II P. Moghe.
Page 12: 125:583 Biointerfacial Characterization of Nanoparticles and Nanoscale Biointerfaces II P. Moghe.
Page 13: 125:583 Biointerfacial Characterization of Nanoparticles and Nanoscale Biointerfaces II P. Moghe.

How to characterize the density and

spatial organization of nanoscale ligands?

Page 14: 125:583 Biointerfacial Characterization of Nanoparticles and Nanoscale Biointerfaces II P. Moghe.

Model System for Clustered Presentation of Ligands

Page 15: 125:583 Biointerfacial Characterization of Nanoparticles and Nanoscale Biointerfaces II P. Moghe.
Page 16: 125:583 Biointerfacial Characterization of Nanoparticles and Nanoscale Biointerfaces II P. Moghe.

Biofunctionalized Comb Polymers

Page 17: 125:583 Biointerfacial Characterization of Nanoparticles and Nanoscale Biointerfaces II P. Moghe.

AFM measurement of ligand clustering

Page 18: 125:583 Biointerfacial Characterization of Nanoparticles and Nanoscale Biointerfaces II P. Moghe.

AFM of Nanospheres for Clustered Biointerfaces

Page 19: 125:583 Biointerfacial Characterization of Nanoparticles and Nanoscale Biointerfaces II P. Moghe.

Characterization of Cell Adhesive Reponses to Nanoscale Clustered

Ligands

Page 20: 125:583 Biointerfacial Characterization of Nanoparticles and Nanoscale Biointerfaces II P. Moghe.

Hypothesis: Presentation of an integrin ligand in a clusteredformat may enhance the efficiency of clustering of ligand-bound integrins in comparison to those elicited byequivalent levels of the ligand presented in a sparse manner.

Alteration in the ligand presentation format may be a basisto alter cell adhesion strength (& motility)

Page 21: 125:583 Biointerfacial Characterization of Nanoparticles and Nanoscale Biointerfaces II P. Moghe.

Characterization of RGD star polymers

Page 22: 125:583 Biointerfacial Characterization of Nanoparticles and Nanoscale Biointerfaces II P. Moghe.

Cell culture and ligand system

• WT NR6 cells, a 3T3-derived murine fibroblast cell linelacking endogenous EGF receptor, transfected with awild type human EGFR (Chen et al., J Cell Biol, 124, 547)These cells express avb3 and a5b1 integrins, which bindto RGD adhesion ligands.

• Cells cultured in MEM-a medium with FBS, P-S,etc.Studies for adhesion & migration excluded FBS and includedHepes buffer.

• YGRGD ligand was presented via polyethylene oxide (PEO)tethers against an inert substrate of radiation-crosslinked PEOhydrogel on PEO-silane treated glass coverslips.

Page 23: 125:583 Biointerfacial Characterization of Nanoparticles and Nanoscale Biointerfaces II P. Moghe.

Ligand and Substrate System

• YGRGD peptide was attached to the PEG hydrogel modifiedcoverslips using star PEO tethers, in order to vary the averagesurface density, and the local spatial distribution (50 nm scale)of RGD peptide. Star PEO has many PEO arms. 1-n RGDpeptides were linked to each start, blocking each unreactedstar arm, and diluting RGD-modified stars with blank stars.These were then grafted to the surface.

• Stars with an average of 1, 5 or 9 ligands per star were achieved. (verified using 125I-YGRGD?)

• Next, RGD conjugated stars and unconjugated stars (in correctproportion, ) were added to PEO hydrogel substrates. Unreactedchain ends were blocked with Tris-HCl. By varying , averageligand densities (1000 (L) - 200,000 (H) molecules/cm2) wereobtained. Average cluster-cluster distance = 6-300 nm.

Page 24: 125:583 Biointerfacial Characterization of Nanoparticles and Nanoscale Biointerfaces II P. Moghe.

Cell Adhesion Assays

• Silanized glass coverslips were glued (!) to35 mm dishes (m) or 24 well plates (a), andincubated with 0.2 ml FN solution/cm2 for 2 h.Substrates were then blocked with BSA for 1 h.FN molecular densities were calculated (assumingeach FN offers 1 integrin binding site?) • A centrifugal cell detachment assay was performed.

Cells were incubated for 12 h (serum-free) in coverslipglued 24 well plates, and medium w/ or w/o EGF was added. Media was filled, wells sealed, and platesspun at 800g for 10 minutes.

Page 25: 125:583 Biointerfacial Characterization of Nanoparticles and Nanoscale Biointerfaces II P. Moghe.

• RGD ligand presentation determines cell-substrate adhesion strength.

Page 26: 125:583 Biointerfacial Characterization of Nanoparticles and Nanoscale Biointerfaces II P. Moghe.